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SUMMARY
Cerebral aspergillosis is a rare cause of brain expansive lesion in AIDS patients. We report the first culture-proven case of
brain abscess due to Aspergillus fumigatus in a Brazilian AIDS patient. The patient, a 26 year-old male with human immunodeficiency
virus (HIV) infection and history of pulmonary tuberculosis and cerebral toxoplasmosis, had fever, cough, dyspnea, and two
episodes of seizures. The brain computerized tomography (CT) showed a bi-parietal and parasagittal hypodense lesion with
peripheral enhancement, and significant mass effect. There was started anti-Toxoplasma treatment. Three weeks later, the patient
presented mental confusion, and a new brain CT evidenced increase in the lesion. He underwent brain biopsy, draining 10 mL of
purulent material. The direct mycological examination revealed septated and hyaline hyphae. There was started amphotericin B
deoxycholate. The culture of the material demonstrated presence of the Aspergillus fumigatus. The following two months, the
patient was submitted to three surgeries, with insertion of drainage catheter and administration of amphotericin B intralesional.
Three months after hospital admission, his neurological condition suffered discrete changes. However, he died due to intrahospital
pneumonia. Brain abscess caused by Aspergillus fumigatus must be considered in the differential diagnosis of the brain expansive
lesions in AIDS patients in Brazil.
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INTRODUCTION
The invasive aspergillosis has emerged as an increasing cause of
morbidity and mortality in immunocompromised patients, especially
these with hematologic cancer (leukemia or lymphoma) and bone
marrow transplant16,20.
The most frequent clinical form is invasive pulmonary aspergillosis
(80-90%)17, which could be disseminated, compromising the central
nervous system (CNS) in up to 10-25% of the cases8,11,17,24. The
neurological manifestations are several, including meningitis,
encephalitis, brain abscess, and/or cerebral infarct. In
neurohistopathological studies, the main manifestations are
hemorrhagic infarcts and abscesses23,31.
The overall case-fatality rate of invasive aspergillosis is
approximately 60% and depend on several factors, including host group,
site of disease, and delayed therapy7,14,15. The case-fatality rate is higher
for bone marrow transplant (~ 90%) and for patients with central
nervous system or disseminated aspergillosis (> 95%)14.
The incidence of invasive aspergillosis in HIV/AIDS patients varies
within 0-12%8.
HIV/AIDS constitutes < 5% of all underlying conditions among
cases with invasive aspergillosis and the third underlying condition
with higher aspergillosis case-fatality rate (~ 80%), after bone marrow
transplant and liver transplant7,14,25.
Cerebral aspergillosis is a rare cause of intracranial mass lesion in
AIDS patients. In this study, we report a fatal case of brain abscess
caused by Aspergillus fumigatus in AIDS patient and review of the
literature.
CASE REPORT
A 26 year-old homosexual male, with HIV infection since 1996,
was admitted in December 1999 at the Instituto de Infectologia Emilio
Ribas, complaining of 10 days with fever, productive cough and
dyspnea, and two episodes of generalized tonic-clonic seizures within
the last 24 hours. He referred history of pulmonary tuberculosis and
cerebral toxoplasmosis with neurologic sequelae characterized by right
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hemiparesis. He reported irregular use of zidovudine, lamivudine,
indinavir, dapsone, pyrimethamine, and folinic acid. Physical
examination disclosed significant weigh loss, paleness, oral thrush,
fever (38.2 ºC), and tachydyspnea. There was also observed non-painful
hepatomegaly and crepitations in the right hemithorax base. The
neurological examination evidenced mental confusion and incomplete,
disproportional, and spastic hemiparesis in the right hemibody. The
rest of the examination was unremarkable. Laboratorial tests detected
moderate anemia (hemoglobin = 10.1 g/dL), leukocytosis (17,800 cells/
mm³) with shift to left (13% of bands), and lymphopenia (8%). The
tests on IgG antibodies against Toxoplasma, Herpes simplex, and
Cytomegalovirus were positive. Two hemocultures showed growing of
Klebsiella pneumoniae. The CD4+ lymphocytes count was 8 cells/mm3.
The chest X-ray evidenced basal lobar consolidation in the right
hemithorax. Brain CT indicated two focal lesions. Only the larger one
present with ring-enhancing and mass effect (Fig. 1). Lumbar tap
showed normal cerebrospinal fluid (CSF), with three leukocytes/mm3,
32 mg/dL of glucose, 38 mg/dL of proteins, and no microorganism in
direct tests and cultures for bacteria, fungus, and mycobacterium.
Besides the supporting measures, ceftriaxone two g/day, fluconazole
100 mg/day, sulfadiazine 1.5 g FID, pyrimethamine 25 mg/day, fonilic
acid 15 mg/day, dexamethasone four mg FID, and phenytoin 100 mg
TID were initiated. Three weeks later, we evidenced important
improvement on his respiratory condition, but the patient persisted
with fever, seizures, and mental confusion. A new CT showed
enlargement of the brain expansive lesion. He underwent trepanation,
draining 10 mL of purulent material. The direct examination
demonstrated presence of septate hyalines hyphae. There was started
amphotericin B deoxycholate 40 mg/day. Three days later, the culture
was indicative of Aspergillus spp., which was later confirmed as
Aspergillus fumigatus. The following two months, the patient was
submitted to three other surgeries, with insertion of drainage catheter
with reservoir, and administration of amphotericin B intralesional. The
direct mycological assays of the material samples drained remained
positive; however, the hemocultures for fungus were persistently
negative. After receiving a total dosage of 2.5 g of amphotericin B
deoxycholate, and due to the occurrence of acute renal insufficiency
(creatinine > 2.5 mg/dL), the medication was changed to 400 mg/day
of itraconazole (PO). At this time, there was no available lipid-
associated amphotericin B preparation in our hospital. The neurological
condition suffered discrete changes, showing fever and mental
confusion, and the polymorphonuclear leukocytes count was normal.
Three months after hospital admission, the patient died due to
intrahospitalar pneumonia. The necropsy was not carried out due to
lack of family consent.
MYCOLOGIC DIAGNOSIS
Direct examination of cerebral tissue with 20% KOH showed the
presence of septate hyphae (Fig. 2). Giemsa stain showed the same
structures. Also, purulent material was cultured on Sabouraud dextrose
agar and brain heart infusion agar, adding chloramphenicol in both,
incubated at 30 oC. After 72 hours, were observed white colonies with
cottoned texture, which turned into dark gray-greenish tonality due to
the formation of spores. The backside of the colonies showed a white
coloration, without diffusible pigment. Slide micro-culture revealed
branched septate hyaline hyphae with conidiophore with smooth wall,
constituted of hemispheric vesicles with greenish color in the upper
part. A single series of phialides, giving origin to rounded and rarely
rough conidia, disposed in long and parallel chain, completed the
characteristics which allowed us to identify the fungus as Aspergillus
fumigatus13 (Fig. 3).
The sensibility profile in vitro was carried out, according to the
protocol for filamentous fungi recommended by the National
Committee for Clinical Laboratory Standards (NCCLS) M38-A18. The
antifungal analyzed were amphotericin B, itraconazole, and
fluconazole, applying the micro-dilution method in RPMI 1640 liquid,
having Candida krusei (ATCC® 6258) and Candida parapsilosis
(ATCC® 22019) as standard species. The values of the minimal
inhibitory concentration (MIC) were 1 µg/mL, 1 µL/mL, and ≥ 32 µL/
mL for amphotericin B, itraconazole, and fluconazole, respectively.
DISCUSSION
This report constitutes, to our knowledge, the first culture-proven
case of brain abscess caused by Aspergillus fumigatus in a Brazilian
AIDS patient.
The clinical presentation of the invasive aspergillosis depends on
clinical condition of the population studied. In general, patients with
severe levels of immunosuppression (i.e. allogeneic bone marrow
transplant recipients) show few symptoms initially and evolve fast
(acute invasive pulmonary aspergillosis). Conversely, less immuno-
compromised patients (i.e. AIDS patients), show usually a more
indolent, symptomatic manifestation that progress slowly (i.e. chronic
invasive pulmonary aspergillosis).
There are few reports on cerebral aspergillosis in patients with
AIDS. A recent literature review identified 33 cases only, including
those with definitive or probable diagnosis17.
Cerebral aspergillosis would come from two different mechanisms:
(i) hematogenic dissemination; or (ii) direct extension of an area
anatomically adjacent to the brain (i.e. sinuses, hear, orbit). In 25% of
patients with AIDS, in the same way as it happened with the current
report, the cerebral aspergillosis could be the only clinical manifestation
of the disease, complicating the diagnosis17.
The main conditions associated to the development of cerebral
aspergillosis in patients with AIDS are neutropenia and the use of
corticosteroids. However, these conditions could not be present17.
The CSF findings on patients with cerebral aspergillosis and AIDS
are unspecified16 and neuroradiological alterations are frequent (~ 85%),
especially showing single lesions (~ 60%)17.
The cerebral aspergillosis radiological findings in
immunocompromised patients include: (i) hypodense cortical and sub-
cortical lesions in CT or hyperintense in T2-weighted MRI,
corresponding to cerebral infartcs; (ii) nodular or ring-enhancing
lesions; and (iii) meningeal enhancement adjacent to the paranasal
sinuses or enhancement of the optical nerve and orbit fat2. These
presentations seem to be related to the level of immunosuppression
and to the stage of the fungal infection6. In patients with severe
immunosuppression (i.e. marrow bone transplant recipients), brain
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of brain biopsies, increasing the number of in vivo diagnoses1. Besides,
imaging techniques, such as thallium-201 single emission computed
tomography (SPECT), positron emission tomography (PET), and
spectroscopy could help in some cases. As for the cerebral aspergillosis,
there is little information available on these techniques12,27.
The treatment of cerebral aspergillosis is difficult and complex.
The approaches include systemic antifungal and surgical treatment of
the abscesses (aspiration or abscess resection)23,24.
The main challenge for the majority of the available antifungal,
such as amphotericin B deoxycholate or liposomal formulations,
itraconazole, and caspofungin, is its limited penetration into the blood-
brain-barrier and/or brain tissue23,24.
The most reported cerebral aspergillosis cases with survival were
not associated to AIDS and received neurosurgical treatment and several
antifungal schemes (amphotericin B deoxycholate, with or without 5-
Fig. 1 - Brain computerized tomography with contrast, showing an extra-axial, bi-parietal,
and parasagittal hypodense lesion with peripheral enhancement and significant perilesional
edema. Another hypodense lesion, without enhancement or expansive effect in the right
frontal region can also be observed.
Fig. 2 - Direct mycological examination of the brain abscess material showing septate hyaline
hyphae (arrow) (X 400).
Fig. 3 - Aspergillus fumigatus microscopic characteristics. A single series of phialides (right
arrow) can be observed, giving origin to the rounded conidia disposed in long and parallel
chains (left arrow) (Lacto phenol cotton blue X400).
lesions, generally, are consistent with acute infarct resulting in a rapid
fatal outcome. In patients with less severe immunosuppression (i.e.
AIDS patients), generally brain lesions show ring or nodular
enhancement consistent with granulomas or abscesses6,19. Aside from
these considerations, as it happened in the current report, the
radiological findings could be varied. Some authors point out that
patients with expansive brain lesions show improved prognostics19.
Nevertheless, the general consensus is that the lethality of all forms of
cerebral aspergillosis, regardless the subjacent disease and radiological
pattern, varies within 90-100%6,14,17,23,24.
Recommendations for evaluation and management of expansive
brain lesions in AIDS patients has been reported elsewhere22. Patients
with positive serology for Toxoplasma gondii must undergo
toxoplasmosis empirical treatment. After 10-14 days, the persistence
or worsening of either clinical symptomatology or the mass lesion
observed on radiographic imaging indicates the performance of brain
biopsy. In some circumstances, the surgical approach must be carried
out at an early stage. Emphasis should be placed to the following
situations: concomitance of negative toxoplasmosis serology and a
single brain lesion22, large lesions with mass effect threatening
herniation22, or high level of suspicion of some alternative diagnostics
to cerebral toxoplasmosis3,29. Patients with suspicion of invasive
aspergillosis and presence of focal brain lesions in radiographic imaging
must be intensively evaluated. This approach could contribute to a
reduction on the number of post-mortem diagnostics, reported in 50%
of the cases17.
In recent years, the availability of molecular methods, applying
the polymerase chain reaction (PCR) in CSF, has been characterized
as “minimally invasive” diagnostic approaches on expansive brain
lesions in AIDS patients. This strategy helped to decrease the number
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fluocytosine; conventional amphotericin in lipidic emulsion, liposomal
amphotericin, ABLC, or itraconazole)4,23. Some studies in patients
without AIDS suggest that the neurosurgical approach improves the
outcome4,26. However, the true value of surgical interventions must be
systematically assessed.
Treatment results of CNS aspergillosis in AIDS patients have been
very disappointing. A review reported inefficacy of any antifungal drugs
associated or not to neurosurgery in 100% of 22 cases17. The antifungals
included amphotericin B deoxycholate, amphotericin B lipidic complex,
or itraconazole. In our case report, the systemic and intralesional use
of the amphotericin B deoxycholate and the repeated surgical drainages
did not help to avoid the lethal evolution.
There is little information available on the clinical use of the
antifungal susceptibility tests for the filamentous fungi, including the
Aspergillus species, despite the recommended reference methods18.
Preliminary information indicates that the MIC > 2 µL/mL for the
amphotericin and the MIC > 8 µL/mL for the itraconazole are associated
to the clinical resistance18. However, the filamentous fungi, usually,
are not susceptible to the fluconazole, showing MICs > 64 µL/mL18.
Considering those breakpoints, the A. fumigatus sample isolated from
the case showed in vitro sensibility to the administrated antifungal
(amphotericin B and itraconazole). However, there were no serum levels
of itraconazol available. For this reason, we did not rule out any problem
related to absorption of this azole. It is presumed that factors related
to the condition of our patient, besides the antifungal susceptibility
could be associated to his outcome. AIDS patients differ from the other
major risk groups in that their underlying disease is progressive and
incurable, complicating any therapeutic approach7.
In addition, reference methods on antifungal susceptibility tests
for filamentous fungi indicate that there are not enough information
available that could demonstrate the correlation between MIC and
clinical outcome with the use of new imidazolic18, including
voriconazole.
Voriconazole is a newly approved imidazolic for the treatment of
invasive aspergillosis that demonstrated higher activity compared to
the amphotericin B10. Different to other antifungal, some studies point
out that this drug shows adequate penetration into the CSF and in the
brain tissue23,24. Despite the inexistence of case reports on cerebral
aspergillosis and AIDS treated with voriconazole available, there are
evidences suggesting its potential use in this population. Six of eight
case reports (seven immunocompromised and one immunocompetent)
revealed a remission of cerebral aspergillosis with the use of
voriconazole, after the unsuccessful use of several antifungal5,15,23,28.
Furthermore, data from clinical and compassionate use programs
support the use of voriconazole, reported a complete or partial response
in 10 (27%) of 37 patients with cerebral aspergillosis9,21,24,30.
Additionally, a recent retrospective study, which evaluated 81 patients
with definitive or probable cerebral aspergillosis treated with
voriconazole, demonstrated complete or partial response and survival
on 35% and 31% of cases, respectively26. Currently, some authors
suggest the use of voriconazole as choice treatment for cerebral
aspergillosis5,24. However, further studies are necessary to determine
more precisely the role of voriconazole in this setting.
In conclusion, brain abscess caused by Aspergillus fumigatus must
be considered in the differential diagnosis of the brain expansive lesions
in AIDS patients. High level of clinical and radiological suspicion could
lead to early diagnostic and treatment approaches of this lethal disease.
RESUMEN
Aspergilosis cerebral causada por Aspergillus fumigatus en
paciente con SIDA: primer reporte de caso demostrado por
cultivo en Brasil
La aspergilosis cerebral es una causa rara de lesión expansiva
cerebral en pacientes con SIDA. Presentamos el primer reporte de un
absceso cerebral causado por Aspergillus fumigatus en un paciente
brasileño con SIDA. El paciente, de 26 años de edad, presentaba
antecedentes de infección por el virus de la inmunodeficiencia humana
(VIH), tuberculosis pulmonar y toxoplasmosis cerebral. Manifestó
fiebre, tos, disnea y dos episódios de convulsiones. La tomografía
computadorizada (TC) demostró una lesión hipodensa parasagital y
bi-parietal con realce periférico e importante efecto de masa. Se inició
tratamiento anti-Toxoplasma. Tres semanas después, el paciente
evidenció confusión mental y una nueva TC de cráneo mostró aumento
de la lesión. Se realizó biopsia cerebral con drenaje de 10 mL de
material purulento. El examen micológico directo reveló hifas hialinas
septadas. Se inició anfotericina B deoxicolato. La cultura del material
demostró presencia de Aspergillus fumigatus. En los siguientes dos
meses el paciente fue sometido a otras tres cirugías, insertándose un
catéter de drenaje y administrándose anfotericina B intralesional. Tres
meses después de la admisión hospitalaria, la condición neurológica
del paciente sufrió discretos cambios. Sin embargo, falleció debido a
neumonia intrahospitalaria. Aunque muy raros, los abscesos cerebrales
causados por Aspergillus fumigatus deben ser considerados en el
diagnóstico diferencial de las lesiones expansivas cerebrales en
pacientes con SIDA.
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